BrainsWay Launches Multicenter Trial of Next-Gen TMS for Alcohol Use Disorder
BrainsWay Ltd. has launched a multicenter clinical trial to evaluate its Deep TMS 360™ technology for treating Alcohol Use Disorder. The trial aims to assess the system's effectiveness in reducing heavy drinking and cravings, marking the first use of BrainsWay's multichannel TMS platform. The study will be conducted in the US, Israel, and Sweden. Results are pending as the trial has just begun.
BrainsWay Ltd. has announced the launch of a multicenter, randomized, controlled clinical trial to evaluate its next-generation Deep TMS 360™ technology for individuals with Alcohol Use Disorder (AUD). The study aims to assess the system’s effectiveness in reducing heavy drinking and cravings. This marks the first multicenter clinical trial using BrainsWay’s multichannel TMS platform, which is designed to provide more comprehensive and uniform brain stimulation, potentially benefiting patients with chronic AUD. The trial will be conducted at research sites across the US, Israel, and Sweden. The results of the study have not yet been presented, as the trial has just been launched. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainsway Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007369), on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
